ICCM files 6-K on Nasdaq Minimum Bid Price Notification

IceCure Medical Ltd. (ICCM) furnished a Form 6-K noting it issued a press release titled “IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification.” The press release is attached as Exhibit 99.1.

Accepted by SEC EDGAR 11/14/2025 - 05:00 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

IceCure Medical Ltd. (ICCM) furnished a Form 6-K noting it issued a press release titled “IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification.” The press release is attached as Exhibit 99.1.

The submission states this report is incorporated by reference into the company’s existing registration statements on Form F-3 (Nos. 333-258660, 333-267272, 333-290046) and Form S-8 (Nos. 333-270982, 333-264578, 333-262620, 333-281587).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ICCM disclose in the Form 6-K?

ICCM furnished a press release titled “IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification,” attached as Exhibit 99.1.

What exhibit was included with ICCM’s 6-K?

Exhibit 99.1, a press release dated November 14, 2025.

Is the 6-K incorporated into ICCM’s registration statements?

Yes. It is incorporated by reference into Form F-3 (Nos. 333-258660, 333-267272, 333-290046) and Form S-8 (Nos. 333-270982, 333-264578, 333-262620, 333-281587).

What is the timeframe of this 6-K report?

The report is for the month of November 2025 and references a press release dated November 14, 2025.

Who signed the 6-K for ICCM?

Chief Executive Officer Eyal Shamir signed the report.

What is the main topic of the attached press release?

The press release concerns receipt of a Nasdaq Minimum Bid Price Notification.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of: November 2025 (Report No. 3)

Commission File Number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F             ☐ Form 40-F

CONTENTS

On November 14, 2025, the Company issued a press release titled “IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification,” a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issuer on Form 6-K. 

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-258660, 333-267272 and 333-290046) and Form S-8 (Registration Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.
99.1		Press release dated November 14, 2025 titled “IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification”.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ICECURE MEDICAL LTD.
Date: November 14, 2025	By:	/s/ Eyal Shamir
		Name:	Eyal Shamir
		Title:	Chief Executive Officer

2